We are live on ! Find out more
CTXR icon

Citius Pharmaceuticals
CTXR

16 hedge funds and large institutions have $1.09M invested in Citius Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

23% more funds holding

Funds holding: 13 → 16 (+3)

0% more capital invested

Capital invested by funds: $1.09M → $1.09M (+$3K)

0.01% less ownership

Funds ownership: 0.09% → 0.08% (-0.01%)

Holders
16
Holders Change
+3
Holders Change %
+23.08%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
5
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$100K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$85.6K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$38K
4
MIM
Miller Investment Management
Pennsylvania
+$28.3K
5
VF
Virtu Financial
New York
+$25.3K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$21.8K
2
Citadel Advisors
Citadel Advisors
Florida
-$20K
3
TSS
Two Sigma Securities
New York
-$12K
4
UBS Group
UBS Group
Switzerland
-$9K
5
OPS
Orion Portfolio Solutions
Nebraska
-$4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$596K +$38K +1,344 +6%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$150K +$85.6K +3,028 +109%
VF
3
Virtu Financial
New York
$119K +$25.3K +897 +24%
SM
4
Sabby Management
Florida
$92K +$100K +3,548 New
Northern Trust
5
Northern Trust
Illinois
$44K +$12K +424 +34%
MIM
6
Miller Investment Management
Pennsylvania
$26K +$28.3K +1,000 New
WSTAM
7
Wilbanks Smith & Thomas Asset Management
Virginia
$21K +$22.6K +800 New
CHA
8
Cooper/Haims Advisors
New York
$10K +$11.3K +400 New
US Bancorp
9
US Bancorp
Minnesota
$10K +$11.3K +400 New
TRCT
10
Tower Research Capital (TRC)
New York
$9K -$21.8K -772 -70%
Osaic Holdings
11
Osaic Holdings
Arizona
$5K +$5.65K +200 New
CP
12
Corbenic Partners
Pennsylvania
$2K – – –
GT
13
Glenmede Trust
Pennsylvania
$2K – – –
Wells Fargo
14
Wells Fargo
California
$2K +$141 +5 +6%
FFA
15
Founders Financial Alliance
North Carolina
$1K +$1.13K +40 New
FCA
16
FinTrust Capital Advisors
South Carolina
$2 +$2.03K +72 New
Citadel Advisors
17
Citadel Advisors
Florida
– -$20K -697 Closed
TSS
18
Two Sigma Securities
New York
– -$12K -418 Closed
UBS Group
19
UBS Group
Switzerland
– -$9K -311 Closed
OPS
20
Orion Portfolio Solutions
Nebraska
– -$4K -144 Closed

CTXR Hedge Fund Activity: Q3 2020 in Review

16 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q3 2020, worth a combined $1.09M — up 0.28% from $1.09M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new CTXR positions and 4 closed out — a net gain of 4 holders — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $100K. The largest seller was Tower Research Capital (TRC), cutting an estimated $21.8K.

  • 16 institutional investors held Citius Pharmaceuticals (CTXR) as of Q3 2020, up from 13 in Q2 2020.
  • Funds reported $1.09M of Citius Pharmaceuticals stock for Q3 2020, up 0.28% quarter-over-quarter.
  • 8 funds opened new Citius Pharmaceuticals positions in Q3 2020 and 4 closed out, a net change of +4 holders.
  • The largest Citius Pharmaceuticals buyer in Q3 2020 was Sabby Management, an estimated $100K added.
  • The largest Citius Pharmaceuticals seller in Q3 2020 was Tower Research Capital (TRC), an estimated $21.8K sold.

Based on aggregated 13F filings for Q3 2020.